Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
A new cooperative research study including Norris Cotton Cancer Center's Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising long term overall survival in patients with metastatic renal cell cancer (mRCC). (Source: World Pharma News)
Source: World Pharma News - July 27, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Immunotherapy Combination in Metastatic RCC Proves Effective
Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab. (Source: CancerNetwork)
Source: CancerNetwork - July 26, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news
Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
(Dartmouth-Hitchcock Medical Center) A novel combination of nivolumab plus ipilimumab for patients with metastatic kidney cancer is proving to be a more effective treatment with more durable tumor response than the two immunotherapies used separately. The promising combination therapy demonstrated manageable safety, notable antitumor activity, and durable responses with better long term overall survival in patients with metastatic renal cell cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 26, 2017 Category: International Medicine & Public Health Source Type: news
FDA Approves Ipilimumab for Pediatric Melanoma
The FDA has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease. (Source: CancerNetwork)
Source: CancerNetwork - July 25, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Melanoma News Pediatric Cancers Source Type: news
U.S. Food and Drug Administration expands approval of Yervoy ® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy ® (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. (Source: World Pharma News)
Source: World Pharma News - July 24, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE) July 24, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 24, 2017 Category: Drugs & Pharmacology Source Type: news
Exelixis and BMS start Phase III combination trial for renal cell carcinoma
Exelixis and Bristol-Myers Squibb (BMS) have started the Phase III CheckMate 9ER clinical trial of Cabometyx (cabozantinib) combined with Opdivo (nivolumab) or both Opdivo and Yervoy (ipilimumab) to treat renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news
SMART Protocol for Mesothelioma Adds Immunotherapy
In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.”
The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 6, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news
Nivolumab Alone or With Ipilimumab Produced Durable Response in SCLC
Treatment with nivolumab alone and in combination with ipilimumab resulted in durable responses in patients with previously treated small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Lung Cancer News Source Type: news
Mesothelioma Clinical Trial Opens with High Expectations
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential.
The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy.
A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - June 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news
Threshold Pharma begins dosing of cancer drugs evofosfamide and ipilimumab in Phase I trial
US-based biopharmaceutical firm Threshold Pharmaceuticals has begun dosing patients in a Phase I clinical trial of evofosfamide in combination with ipilimumab to treat various cancers. (Source: Drug Development Technology)
Source: Drug Development Technology - June 14, 2017 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
Bristol-Myers Squibb Company (NYSE:BMY) announced today it has entered into a clinical research collaboration with Novartis to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist® (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR). (Source: World Pharma News)
Source: World Pharma News - June 5, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
Amgen Presents New Phase 2 Data On IMLYGIC ® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
First Randomized Study to Evaluate the Combination of IMLYGIC, an Oncolytic Viral Therapy, With a Checkpoint Inhibitor
Data Demonstrate IMLYGIC in Combination With YERVOY® (Ipilimumab) Doubled Objective Response Rate in Unresectable Advanced Melanoma
Responses Not Limited to Injected Lesions; 50 Percent or Higher Reduction in Visceral Lesion Size Occurred More Frequently in Patients in the Combination Arm
THOUSAND OAKS, Calif., June 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC® (talimogene laherparepvec) in combination with the immune...
Source: Amgen News Release - June 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Array BioPharma and BMS to assess cancer drugs in Phase I/II combination trial
Array BioPharma has entered a strategic clinical research collaboration with Bristol-Myers Squibb (BMS) to evaluate the combination of binimetinib with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in a Phase I/II clinical trial to trea … (Source: Drug Development Technology)
Source: Drug Development Technology - May 31, 2017 Category: Pharmaceuticals Source Type: news
